U.S. FDA Approval of Lombard's Aorfix

Aorfix is approved to treat patients with aneurysm neck angles of 0-90°, which represents most patients with abdominal aortic aneurysms ("AAA").

Aorfix is the only product approved in the US to treat patients with neck angulation of greater
than 60°.

Clinical data from Lombard's PYTHAGORAS study show that in the difficult to treat patients with neck angles of greater than 60% the product performed well.

Approval triggers both an equity and debt financing to support the US launch.

Lombard Medical Technologies plc

Lombard Medical Technologies plc
AAA stent graft manufacturer

Latest News

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera

MVM Life Science Partners LLP closes MVM IV

MVM Life Science Partners LLP announces the closing of a $233 million healthcare fund, MVM IV.